Literature DB >> 12735932

Occurrence of GH deficiency in adult patients who underwent neurosurgery in the hypothalamus-pituitary area for non-functioning tumour masses.

G Corneli1, R Baldelli, C Di Somma, S Rovere, D Gaia, M Pellegrino, V Gasco, C Durante, S Grottoli, A Colao, G Tamburrano, G Lombardi, E Ghigo, G Aimaretti.   

Abstract

Hypothalamus-pituitary tumours and their treatments (neurosurgery and/or radiotherapy) are major causes of acquired hypopituitarism. Scientific and clinical evidences show the positive effect of GH replacement therapy in severe adult GH deficiency (GHD) pointed toward the need of diagnostic screening of conditions at high risk for GHD. We screened 152 adults (82 males, 70 females; age: 52.3+/-1.2 years, age-range: 20-80 years, BMI: 26.4+/-0.8 kg/m(2)) in order to disclose the presence of GHD after neurosurgery for hypothalamus-pituitary tumours. The whole group (studied at least 3 months after neurosurgery) included: 111 non-functioning pituitary adenomas and 41 peri-pituitary tumours (24 craniopharyngiomas, 7 meningiomas, 5 cysts, 2 chondrosarcomas, 1 colesteatoma, 1 germinoma and 1 hemangiopericitoma). In 14 patients who underwent both neurosurgery and radiotherapy due to a tumour remnant, the somatotroph function was evaluated again 6 months after the end of radiotherapy. GHD was assumed to be shown by GH peak <5 microg/L (severe <3 microg/L) after Insulin Tolerance Test (ITT) or <16.5 microg/L (severe <9 microg/L) after GH-releasing hormone+arginine test (GHRH+ARG) (3rd and 1st centile limits of normality, respectively), two widely accepted provocative tests. Before neurosurgery GHD was present in 97/152 (63.8%) and resulted severe in 66/152 (43.4%) patients. After neurosurgery GHD was present in 122/152 (80.2%) and severe in 106/152 (69.7%). While 26 patients developed severe GHD (GHD) as consequence of neurosurgery, only one patient who had been classified as GHD before neurosurgery showed normal GH response after surgery. After neurosurgery, 91.0% (81/89) of the pan-hypopituitaric patients showed severe GHD. Considering the 14 patients who underwent also radiotherapy after neurosurgery, 7/14 had GHD before neurosurgery while 12/14 became severe GHD after radiotherapy in a context of pan-hypopituitarism. IGF-I levels below the 3rd age-related normal limits were present in 39.0% of patients in whom severe GHD was showed by provocative tests. In conclusion, this study shows that the occurrence of acquired severe GHD is extremely common in adult patients bearing non-functioning tumour masses in the hypothalamus-pituitary area and further increases after neurosurgery. All patients bearing non-functioning hypothalamus-pituitary tumours should undergo evaluation of their somatotroph function before and after neurosurgery that represents a condition at obvious more than high risk for hypopituitarism.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12735932     DOI: 10.1016/s1096-6374(03)00010-8

Source DB:  PubMed          Journal:  Growth Horm IGF Res        ISSN: 1096-6374            Impact factor:   2.372


  10 in total

Review 1.  Traumatic brain injury-induced hypopituitarism in adolescence.

Authors:  Roberto Baldelli; Simonetta Bellone; Ginevra Corneli; Silvia Savastio; Antonella Petri; Gianni Bona
Journal:  Pituitary       Date:  2005       Impact factor: 4.107

2.  Characteristics of adult patients with growth hormone deficiency who underwent neurosurgery for functioning and non-functioning pituitary adenomas and craniopharyngiomas.

Authors:  R Baldelli; A Bianchi; F Diacono; M Passeri; A Fusco; D Valle; M Poggi; M Terlini; V Toscano; G Tamburrano; A Pontecorvi; G Maira; L De Marinis
Journal:  J Endocrinol Invest       Date:  2005-02       Impact factor: 4.256

3.  Identification of new biomarkers of low-dose GH replacement therapy in GH-deficient patients.

Authors:  Diana Cruz-Topete; Jens Otto L Jorgensen; Britt Christensen; Lucila Sackmann-Sala; Thomas Krusenstjerna-Hafstrøm; Adam Jara; Shigeru Okada; John J Kopchick
Journal:  J Clin Endocrinol Metab       Date:  2011-05-04       Impact factor: 5.958

4.  Progression of pituitary tumours: impact of GH secretory status and long-term GH replacement therapy.

Authors:  Valentina Gasco; Marina Caputo; Valeria Cambria; Guglielmo Beccuti; Mirko Parasiliti Caprino; Ezio Ghigo; Mauro Maccario; Silvia Grottoli
Journal:  Endocrine       Date:  2018-10-19       Impact factor: 3.633

Review 5.  Postoperative assessment of the patient after transsphenoidal pituitary surgery.

Authors:  John C Ausiello; Jeffrey N Bruce; Pamela U Freda
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

6.  Pituitary insufficiency after operation of supratentorial intra- and extraaxial tumors outside of the sellar-parasellar region?

Authors:  Dorothee Wachter; Nicole Gondermann; Matthias F Oertel; Ulf Nestler; Veit Rohde; Dieter-Karsten Böker
Journal:  Neurosurg Rev       Date:  2011-06-15       Impact factor: 3.042

Review 7.  Endocrinological disorders affecting neurosurgical patients: An intensivists perspective.

Authors:  Sukhminder Jit Singh Bajwa; Rudrashish Haldar
Journal:  Indian J Endocrinol Metab       Date:  2014-11

Review 8.  Challenges in the Diagnosis and Management of Growth Hormone Deficiency in India.

Authors:  Mathew John; Ekaterina Koledova; Kanakatte Mylariah Prasanna Kumar; Harshal Chaudhari
Journal:  Int J Endocrinol       Date:  2016-10-27       Impact factor: 3.257

9.  Quantitative Analysis of Proteome in Non-functional Pituitary Adenomas: Clinical Relevance and Potential Benefits for the Patients.

Authors:  Tingting Cheng; Ya Wang; Miaolong Lu; Xiaohan Zhan; Tian Zhou; Biao Li; Xianquan Zhan
Journal:  Front Endocrinol (Lausanne)       Date:  2019-12-05       Impact factor: 5.555

Review 10.  Growth hormone levels in the diagnosis of growth hormone deficiency in adulthood.

Authors:  Ginevra Corneli; Valentina Gasco; Flavia Prodam; Silvia Grottoli; Gianluca Aimaretti; Ezio Ghigo
Journal:  Pituitary       Date:  2007       Impact factor: 3.599

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.